Ani Pharmaceuticals [ANIP] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Ani Pharmaceuticals Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Ani Pharmaceuticals Inc. wins in 8 metrics, Haleon Plc - ADR wins in 12 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Ani Pharmaceuticals Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) 24.08 18.72 Haleon Plc - ADR
Price-to-Book Ratio 3.10 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 116.19 52.37 Haleon Plc - ADR
PEG Ratio -0.07 15.42 Haleon Plc - ADR
EV/EBITDA 11.46 33.08 Ani Pharmaceuticals Inc.
Profit Margin (TTM) 8.87% 15.11% Haleon Plc - ADR
Operating Margin (TTM) 11.99% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) 11.99% 23.17% Haleon Plc - ADR
Return on Equity 16.16% 10.27% Ani Pharmaceuticals Inc.
Return on Assets (TTM) 3.82% 4.67% Haleon Plc - ADR
Free Cash Flow (TTM) $150.90M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 33.70% -20.18% Ani Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 2.06 3.78 Ani Pharmaceuticals Inc.
Enterprise Value $2.00B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 2.27 8.23 Ani Pharmaceuticals Inc.
Gross Profit Margin (TTM) 59.42% 55.38% Ani Pharmaceuticals Inc.
Revenue per Share (TTM) $44 $2 Ani Pharmaceuticals Inc.
Earnings per Share (Diluted) $3.32 $0.50 Ani Pharmaceuticals Inc.
Beta (Stock Volatility) 0.44 0.33 Haleon Plc - ADR
Short % of Float 19.22% 0.43% Haleon Plc - ADR

Ani Pharmaceuticals Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

ANIP
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Ani Pharmaceuticals Inc.-2.69%-8.30%-9.32%-0.76%-9.10%-4.82%
Haleon Plc - ADR-1.58%-5.84%-5.84%-19.96%-10.03%-13.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Ani Pharmaceuticals Inc.33.70%63.56%128.36%43.87%-27.55%-28.50%
Haleon Plc - ADR-20.18%9.16%22.27%22.27%22.27%22.27%

Performance & Financial Health Analysis: Ani Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricANIPHLN
Market Information
Market Cap i$1.78B$42.40B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i380,5356,594,249
90 Day Avg. Volume i370,6187,985,230
Last Close$74.65$8.70
52 Week Range$58.70 - $99.50$8.69 - $11.42
% from 52W High-24.97%-23.82%
All-Time High$450.00 (May 29, 2000)$11.42 (Jun 02, 2025)
% from All-Time High-83.41%-23.82%
Growth Metrics
Quarterly Revenue Growth0.30%0.01%
Quarterly Earnings Growth0.30%0.86%
Financial Health
Profit Margin (TTM) i0.09%0.15%
Operating Margin (TTM) i0.12%0.23%
Return on Equity (TTM) i0.16%0.10%
Debt to Equity (MRQ) i116.1952.37
Cash & Liquidity
Book Value per Share (MRQ)$25.81$4.99
Cash per Share (MRQ)$14.12$0.15
Operating Cash Flow (TTM) i$185.22M$3.56B
Levered Free Cash Flow (TTM) i$119.42M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Ani Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricANIP (Apr 24, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i24.0818.72
Forward P/E i7.5515.42
PEG Ratio i-0.0715.42
Price to Sales (TTM) i2.063.78
Price to Book (MRQ) i3.101.88
Market Capitalization
Market Capitalization i$1.78B$42.40B
Enterprise Value i$2.00B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i2.278.23
Enterprise to EBITDA i11.4633.08
Risk & Other Metrics
Beta i0.440.33
Book Value per Share (MRQ) i$25.81$4.99

Financial Statements Comparison: Ani Pharmaceuticals Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricANIP (2025)HLN (2025)
Revenue/Sales i883.37M11.03B
Cost of Goods Sold i341.31M3.95B
COGS % of Revenue i38.6%35.8%
Gross Profit i542.06M7.08B
Gross Margin i61.4%64.2%
Research & Development i51.66M316.00M
Operating Income (EBIT) i81.23M2.41B
Operating Margin i9.2%21.9%
EBITDA i174.58M2.81B
EBITDA Margin i19.8%25.5%
Pre-Tax Income i95.79M2.15B
Pre-Tax Income % of Revenue i10.8%19.5%
Income Tax i17.45M472.00M
Income Tax % of Revenue i2.0%4.3%
Net Income (Profit) i78.34M1.68B
Profit Margin i8.9%15.2%

Balance Sheet & Liquidity Metrics

MetricANIP (2025)HLN (2025)
Cash & Equivalents i285.59M1.26B
Total Current Assets i753.12M4.55B
Total Current Assets % of Revenue i85.3%41.3%
Total Current Liabilities i278.11M4.93B
Total Current Liabilities % of Revenue i31.5%44.7%
Long-Term Debt i599.77M7.75B
Long-Term Debt % of Revenue i67.9%70.2%
Total Shareholders Equity i540.72M16.48B
Retained Earnings i-23.10M27.85B
Retained Earnings % of Revenue i-2.6%252.5%
Property, Plant & Equipment i650,0001.00M

Cash Flow Statement Comparison

MetricANIP (2025)HLN (2025)
Operating Cash Flow i139.39M2.19B
Operating Cash Flow % of Revenue i15.8%19.8%
Capital Expenditures i-13.84M-322.00M
Free Cash Flow i150.90M2.22B
FCF Margin i17.1%20.1%
Debt Repayment i-10.16M-1.35B
Common Stock Repurchase i-12.21M-654.00M

Short Interest & Institutional Ownership Analysis

MetricANIPHLN
Shares Short i3.58M19.28M
Short Ratio i9.942.14
Short % of Float i19.22%0.43%
Shares Outstanding i22.49M8.91B
Float Shares i19.34M8.86B
% Held by Insiders i7.37%0.01%
% Held by Institutions i99.81%12.74%
% Held by Public i-7.18%87.25%

Dividend Analysis & Yield Comparison: Ani Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricANIPHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025